Clinical Trials
34 trialsAMYLOCARP
Ramsay Générale de Santé
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
MGUS-PET
University of Zurich
CArdiag
Lantheus Biosciences Ltd.
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Stanford University
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Fondazione IRCCS Policlinico San Matteo di Pavia
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Kedrion S.p.A.
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Attralus, Inc.
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
ALPS
Fondazione IRCCS Policlinico San Matteo di Pavia
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Institute of Hematology & Blood Diseases Hospital, China
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
ReAL
Fondazione IRCCS Policlinico San Matteo di Pavia
EUREKA
Fondazione IRCCS Policlinico San Matteo di Pavia
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
ETCABIO
University Hospital, Angers
ITA-WebNet
Fondazione IRCCS Policlinico San Matteo di Pavia
ALACRITY
Alexion Pharmaceuticals, Inc.
B-SCR-MM
Ohio State University Comprehensive Cancer Center
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
ALANIS
GlaxoSmithKline
MED-hATTR
The Cleveland Clinic
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
BMT
Massachusetts General Hospital
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital